About Integra Lifesciences Holdings Corp (NASDAQ:IART)
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:IART
- CUSIP: 45798520
- Web: www.integralife.com/
- Market Cap: $4.02 billion
- Outstanding Shares: 78,078,000
- 50 Day Moving Avg: $50.62
- 200 Day Moving Avg: $49.69
- 52 Week Range: $37.71 - $56.42
Sales & Book Value:
- Trailing P/E Ratio: 62.80
- Foreward P/E Ratio: 23.30
- P/E Growth: 2.39
- Annual Revenue: $1.05 billion
- Price / Sales: 3.83
- Book Value: $11.55 per share
- Price / Book: 4.46
- EBITDA: $240.98 million
- Net Margins: 3.84%
- Return on Equity: 4.98%
- Return on Assets: 2.09%
- Debt-to-Equity Ratio: 0.97%
- Current Ratio: 3.46%
- Quick Ratio: 2.14%
- Average Volume: 576,815 shs.
- Beta: 0.71
- Short Ratio: 6.29
Frequently Asked Questions for Integra Lifesciences Holdings Corp (NASDAQ:IART)
What is Integra Lifesciences Holdings Corp's stock symbol?
Integra Lifesciences Holdings Corp trades on the NASDAQ under the ticker symbol "IART."
When did Integra Lifesciences Holdings Corp's stock split? How did Integra Lifesciences Holdings Corp's stock split work?
Integra Lifesciences Holdings Corp shares split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were payable to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences Holdings Corp stock prior to the split would have 200 shares after the split.
How were Integra Lifesciences Holdings Corp's earnings last quarter?
Integra Lifesciences Holdings Corp (NASDAQ:IART) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $0.45 EPS for the quarter, hitting the Zacks' consensus estimate of $0.45. The business had revenue of $282.16 million for the quarter, compared to analyst estimates of $283.58 million. Integra Lifesciences Holdings Corp had a return on equity of 4.98% and a net margin of 3.84%. The company's quarterly revenue was up 13.2% compared to the same quarter last year. During the same period last year, the firm posted $0.40 earnings per share. View Integra Lifesciences Holdings Corp's Earnings History.
When will Integra Lifesciences Holdings Corp make its next earnings announcement?
What guidance has Integra Lifesciences Holdings Corp issued on next quarter's earnings?
Integra Lifesciences Holdings Corp issued an update on its FY17 earnings guidance on Wednesday, July, 26th. The company provided EPS guidance of $1.88-1.94 for the period, compared to the Thomson Reuters consensus estimate of $1.92. The company issued revenue guidance of $1.125-1.14 billion, compared to the consensus revenue estimate of $1.13 billion.
Where is Integra Lifesciences Holdings Corp's stock going? Where will Integra Lifesciences Holdings Corp's stock price be in 2017?
9 analysts have issued twelve-month target prices for Integra Lifesciences Holdings Corp's stock. Their forecasts range from $46.00 to $65.00. On average, they expect Integra Lifesciences Holdings Corp's stock price to reach $53.56 in the next twelve months. View Analyst Ratings for Integra Lifesciences Holdings Corp.
Who are some of Integra Lifesciences Holdings Corp's key competitors?
Some companies that are related to Integra Lifesciences Holdings Corp include Steris Plc (STE), West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), Hill-Rom Holdings (HRC), VWR Corporation (VWR), DexCom (DXCM), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), NuVasive (NUVA), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Halyard Health (HYH), Inogen (INGN), CONMED (CNMD), MiMedx Group (MDXG), OraSure Technologies (OSUR) and Asante Solutions (PUMP).
Who are Integra Lifesciences Holdings Corp's key executives?
Integra Lifesciences Holdings Corp's management team includes the folowing people:
- Stuart M. Essig Ph.D., Independent Chairman of the Board
- Peter J. Arduini, President, Chief Executive Officer, Director
- Glenn G. Coleman, Chief Financial Officer, Principal Accounting Officer, Corporate Vice President
- Lisa Evoli, Corporate Vice President, Chief Human Resources Officer
- Kenneth Burhop Ph.D., Chief Scientific Officer, Corporate Vice President
- John Mooradian, Corporate Vice President - Global Operations and Supply Chain
- Richard D. Gorelick, Corporate Vice President, General Counsel, Administration, Secretary
- Robert T. Davis Jr., Corporate Vice President, President — Specialty Surgical Solutions
- Judith E. O'Grady R.N., Corporate Vice President - Global Regulatory Affairs
- Daniel L. Reuvers, Corporate Vice President, President - Specialty Surgical Solutions
Who owns Integra Lifesciences Holdings Corp stock?
Integra Lifesciences Holdings Corp's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (1.29%), Tributary Capital Management LLC (0.48%), Nationwide Fund Advisors (0.15%), Quantitative Systematic Strategies LLC (0.01%) and Whittier Trust Co. (0.00%). Company insiders that own Integra Lifesciences Holdings Corp stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Donald E Morel Jr, Glenn Coleman, James M Sullivan, Joseph Vinhais, Peter J Arduini, Raymond G Murphy, Richard D Gorelick and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences Holdings Corp.
Who sold Integra Lifesciences Holdings Corp stock? Who is selling Integra Lifesciences Holdings Corp stock?
Integra Lifesciences Holdings Corp's stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors, Fisher Asset Management LLC and Tributary Capital Management LLC. Company insiders that have sold Integra Lifesciences Holdings Corp stock in the last year include Glenn Coleman, James M Sullivan, Peter J Arduini and Stuart Essig. View Insider Buying and Selling for Integra Lifesciences Holdings Corp.
Who bought Integra Lifesciences Holdings Corp stock? Who is buying Integra Lifesciences Holdings Corp stock?
Integra Lifesciences Holdings Corp's stock was acquired by a variety of institutional investors in the last quarter, including Quantitative Systematic Strategies LLC and Whittier Trust Co.. Company insiders that have bought Integra Lifesciences Holdings Corp stock in the last two years include Barbara B Hill and Donald E Morel Jr. View Insider Buying and Selling for Integra Lifesciences Holdings Corp.
How do I buy Integra Lifesciences Holdings Corp stock?
Shares of Integra Lifesciences Holdings Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Integra Lifesciences Holdings Corp's stock price today?
MarketBeat Community Rating for Integra Lifesciences Holdings Corp (NASDAQ IART)MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences Holdings Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Integra Lifesciences Holdings Corp stock can currently be purchased for approximately $51.50.
Consensus Ratings for Integra Lifesciences Holdings Corp (NASDAQ:IART) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 7 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.78)|
|Consensus Price Target: ||$53.56 (3.99% upside)|Consensus Price Target History for Integra Lifesciences Holdings Corp (NASDAQ:IART)
Analysts' Ratings History for Integra Lifesciences Holdings Corp (NASDAQ:IART)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/12/2017||Jefferies Group LLC||Reiterated Rating||Buy||$58.00||N/A|
|9/18/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Buy||$60.00||Low|
|9/12/2017||Barclays PLC||Reiterated Rating||Equal Weight||$47.00 -> $53.00||High|
|7/27/2017||Raymond James Financial, Inc.||Boost Price Target||Outperform||$51.00 -> $55.00||Low|
|7/26/2017||Cantor Fitzgerald||Set Price Target||Buy||$65.00||Low|
|5/2/2017||Royal Bank Of Canada||Reiterated Rating||Sector Perform -> Sector Perform||$46.00 -> $48.00||Low|
|3/22/2017||Piper Jaffray Companies||Reiterated Rating||Overweight||$47.00||Low|
|1/6/2017||JMP Securities||Upgrade||Market Perform -> Outperform||$50.00||N/A|
|10/28/2016||Lake Street Capital||Upgrade||Hold -> Buy||$46.00||N/A|
|9/23/2016||Argus||Boost Price Target||Buy||$45.00 -> $52.50||N/A|
|7/13/2016||J P Morgan Chase & Co||Initiated Coverage||Overweight||N/A|
|11/12/2015||Citigroup Inc.||Initiated Coverage||Buy||$37.50||N/A|
Earnings History for Integra Lifesciences Holdings Corp (NASDAQ:IART)Earnings History by Quarter for Integra Lifesciences Holdings Corp (NASDAQ IART)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/26/2017||Q2 2017||$0.45||$0.45||$283.58 million||$282.16 million||View||N/A|
|4/26/2017||Q1 17||$0.40||$0.39||$254.19 million||$258.60 million||View||N/A|
|2/23/2017||Q4 2016||$0.52||$0.52||$257.27 million||$255.70 million||View||N/A|
|10/27/2016||Q3||$0.89||$0.93||$249.30 million||$250.30 million||View||Listen|
|7/28/2016||Q216||$0.76||$0.79||$243.17 million||$249.30 million||View||Listen|
|4/27/2016||Q116||$0.73||$0.74||$230.66 million||$236.80 million||View||Listen|
|2/25/2016||Q4||$0.86||$0.87||$241.11 million||$241.20 million||View||Listen|
|11/3/2015||Q315||$0.74||$0.75||$224.08 million||$226.40 million||View||Listen|
|7/30/2015||Q215||$0.73||$0.79||$239.91 million||$244.10 million||View||Listen|
|4/30/2015||Q115||$0.63||$0.76||$229.69 million||$233.70 million||View||N/A|
|2/24/2015||Q414||$0.89||$0.94||$244.39 million||$252.20 million||View||Listen|
|11/3/2014||Q314||$0.74||$0.76||$233.50 million||$229.70 million||View||Listen|
|8/5/2014||Q214||$0.63||$0.68||$229.32 million||$231.40 million||View||N/A|
|5/1/2014||Q114||$0.58||$0.57||$213.30 million||$215.00 million||View||N/A|
|2/25/2014||Q413||$0.81||$0.78||$223.37 million||$220.80 million||View||N/A|
|10/28/2013||Q313||$0.70||$0.72||$214.05 million||$213.20 million||View||N/A|
|8/1/2013||Q2 2013||$0.55||$0.60||$207.30 million||$205.50 million||View||N/A|
|5/2/2013||Q1 2013||$0.37||$0.39||$195.20 million||$196.70 million||View||N/A|
|2/21/2013||Q4 2012||$0.76||$0.78||$215.90 million||$214.40 million||View||N/A|
Earnings Estimates for Integra Lifesciences Holdings Corp (NASDAQ:IART)
2017 EPS Consensus Estimate: $1.91
2018 EPS Consensus Estimate: $2.27
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Integra Lifesciences Holdings Corp (NASDAQ:IART)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Integra Lifesciences Holdings Corp (NASDAQ:IART)
Insider Ownership Percentage: 21.50%Insider Trades by Quarter for Integra Lifesciences Holdings Corp (NASDAQ:IART)
Institutional Ownership Percentage: 84.90%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/4/2017||Donald E Morel Jr||Director||Buy||10,000||$49.25||$492,500.00|| |
|8/3/2017||Donald E Morel Jr||Director||Buy||2,500||$49.29||$123,225.00|| |
|8/1/2017||Barbara B Hill||Director||Buy||5,050||$49.33||$249,116.50|| |
|5/25/2017||Stuart Essig||Director||Sell||135,000||$49.90||$6,736,500.00|| |
|5/23/2017||Stuart Essig||Director||Sell||140,000||$48.01||$6,721,400.00|| |
|5/4/2017||Glenn Coleman||VP||Sell||13,865||$45.91||$636,542.15|| |
|5/4/2017||James M Sullivan||Director||Sell||15,658||$45.89||$718,545.62|| |
|11/8/2016||Peter J Arduini||CEO||Sell||24,009||$79.51||$1,908,955.59|| |
|8/23/2016||Raymond G Murphy||Director||Sell||2,600||$86.64||$225,264.00|| |
|8/9/2016||Peter J Arduini||CEO||Sell||24,009||$84.52||$2,029,240.68|| |
|8/4/2016||Raymond G Murphy||Director||Sell||2,610||$84.83||$221,406.30|| |
|8/1/2016||Richard D Gorelick||VP||Sell||4,000||$84.60||$338,400.00|| |
|5/9/2016||Joseph Vinhais||VP||Sell||972||$73.36||$71,305.92|| |
|5/4/2016||Glenn Coleman||CFO||Sell||3,563||$70.62||$251,619.06|| |
|5/3/2016||Christian S Schade||Director||Sell||7,829||$70.42||$551,318.18|| |
|5/2/2016||Daniel L Reuvers||VP||Sell||1,000||$71.43||$71,430.00|| |
|4/29/2016||Richard D Gorelick||VP||Sell||4,000||$70.72||$282,880.00|| |
|4/27/2016||Stuart Essig||Director||Sell||104,390||$70.15||$7,322,958.50|| |
|4/6/2016||Stuart Essig||Director||Sell||21,100||$66.19||$1,396,609.00|| |
|4/5/2016||Stuart Essig||Director||Sell||83,290||$66.68||$5,553,777.20|| |
|4/4/2016||Stuart Essig||Director||Sell||42,150||$67.26||$2,835,009.00|| |
|5/7/2015||Stuart Essig||Director||Sell||75,000||$64.32||$4,824,000.00|| |
|5/6/2015||Stuart Essig||Director||Sell||125,000||$64.83||$8,103,750.00|| |
|1/2/2015||Judith Ogrady||VP||Sell||3,500||$53.33||$186,655.00|| |
|10/28/2014||Stuart Essig||Director||Sell||147,098||$49.58||$7,293,118.84|| |
|10/27/2014||Stuart Essig||Director||Sell||41,268||$49.56||$2,045,242.08|| |
|9/2/2014||Judith Ogrady||VP||Sell||2,500||$49.82||$124,550.00|| |
|8/27/2014||Richard D Gorelick||VP||Sell||7,000||$50.03||$350,210.00|| |
|8/25/2014||John B Henneman III||CAO||Sell||20,000||$50.12||$1,002,400.00|| |
|8/22/2014||Deborah A Leonetti||VP||Sell||1,000||$50.96||$50,960.00|| |
|8/8/2014||Brian Larkin||VP||Sell||1,947||$48.28||$94,001.16|| |
|7/30/2014||Stuart Essig||Director||Sell||50,800||$47.76||$2,426,208.00|| |
|7/23/2014||Stuart Essig||Director||Sell||27,819||$47.80||$1,329,748.20|| |
|7/1/2014||Judith Ogrady||VP||Sell||2,500||$47.54||$118,850.00|| |
|6/23/2014||Stuart Essig||Director||Sell||21,381||$47.76||$1,021,156.56|| |
|4/3/2014||Stuart Essig||Director||Sell||6,344||$46.01||$291,887.44|| |
|4/2/2014||Stuart Essig||Director||Sell||76,177||$46.05||$3,507,950.85|| |
|3/31/2014||Stuart Essig||Director||Sell||17,479||$46.05||$804,907.95|| |
|3/10/2014||Deborah Leonetti||VP||Sell||7,563||$49.22||$372,250.86|| |
|3/4/2014||Richard Gorelick||VP||Sell||2,000||$47.98||$95,960.00|| |
|2/28/2014||Christian Schade||Director||Sell||7,500||$47.06||$352,950.00|| |
|2/27/2014||Brian Larkin||VP||Sell||3,265||$46.15||$150,679.75|| |
|2/27/2014||John Henneman III||CFO||Sell||5,000||$46.07||$230,350.00|| |
|1/16/2014||Stuart Essig||Director||Sell||8,037||$49.59||$398,554.83|| |
|1/14/2014||Stuart Essig||Director||Sell||10,600||$49.50||$524,700.00|| |
|1/13/2014||Stuart Essig||Director||Sell||99,032||$49.51||$4,903,074.32|| |
|1/9/2014||Stuart Essig||Director||Sell||114,431||$49.58||$5,673,488.98|| |
|8/30/2013||Richard Gorelick||VP||Sell||3,000||$40.79||$122,370.00|| |
|8/23/2013||Deborah Leonetti||VP||Sell||8,906||$41.68||$371,202.08|| |
|8/19/2013||Brian Larkin||VP||Sell||7,490||$41.90||$313,831.00|| |
|8/19/2013||John Henneman III||CFO||Sell||30,000||$42.08||$1,262,400.00|| |
|8/1/2013||Judith Ogrady||VP||Sell||1,000||$39.50||$39,500.00|| |
|7/30/2013||Judith Ogrady||VP||Sell||2,000||$38.50||$77,000.00|| |
|5/31/2013||Jerry E Corbin||VP||Sell||1,876||$38.07||$71,419.32|| |
Headline Trends for Integra Lifesciences Holdings Corp (NASDAQ:IART)
Latest Headlines for Integra Lifesciences Holdings Corp (NASDAQ:IART)
Loading headlines, please wait.
Integra Lifesciences Holdings Corp (IART) Chart for Monday, October, 23, 2017